Medical and Science
Australia’s clinical trials edge: High quality meets hidden friction

Clinical trials are often wrapped in the language of hope. But in 2026, they are equally a test of competitive edge and whether Australia risks being left behind.
Marking Clinical Trials Day (20 May), Melissa Simpson, Associate Director of Clinical Development Centre (CDC) at Novo Nordisk Oceania, steps into this Health Industry Hub podcast series to unpack what it means to operate inside a clinical research environment increasingly defined by speed, investment pressure, and fierce international competition.
Against this backdrop, the discussion examines why reforms such as the National One Stop Shop (NOSS) and National Clinical Trials Front Door have become more than policy projects and are increasingly seen as tests of national intent.
Simpson also reflects on the mounting pressure to design trials that genuinely reflect the people medicine is meant to serve. From underserved populations historically overlooked in trial data to the persistent imbalance in women’s representation, the conversation interrogates whether diversity in clinical research is still being treated as a future ambition rather than a non-negotiable standard.
Looking ahead, the discussion turns toward the next phase of disruption reshaping the sector, from decentralised trial models to the intensifying global race to harness the full potential of artificial intelligence (AI) across clinical development.
🎧Access the Clinical Trials Day podcast series:
- Clinical trials sector faces defining test as Asia-Pacific competition intensifies >>>
- A clinician’s view from the frontline of curative-intent cancer therapies: Dr Karthik Nath >>>
- Digital twins and AI patient selection reshape clinical trials ecosystem >>>
- Australia’s clinical trials edge: High quality meets hidden friction >>>
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News - MedTech & Diagnostics
Roche unlocks new horizons for genomic research in Asia Pacific
Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]
MoreNews - Pharmaceuticals
‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly
The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]
MoreNews - MedTech & Diagnostics
More public hospitals turn to same-day hip and knee surgery, but key blind spots persist
Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]
MoreNews - Pharmaceuticals
TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning
The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]
More